Qi Qiu

Qi Qiu

Auto-generated profile, based on publicly available information

Qi Qiu

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
HXHuihui Xu
Huihui Xu
HZHongyan Zhao
Hongyan Zhao
CLCheng Lu
Cheng Lu
QQQi Qiu
Qi Qiu
GWGui Wang
Gui Wang
CXCheng Xiao
Cheng Xiao
Triptolide, a purified component ofTripterygiumwilfordii Hook F, has been shown to have immunosuppressive and anti-inflammatory properties in rheumatoid arthritis (RA). Although triptolide has demonstrated that it could suppress bone destruction in collagen-induced mice, its therapeutic mechanism remains unclear. Many studies have investigated the effect of triptolide on Tregs and Tregs-related cytokine involved in RA. Additionally, previous studies have implied that Tregs inhibit osteoclast differentiation and bone resorption. Thus, in this study we aimed to explore the regulatory mechanism by which triptolide influences the Treg-mediated production of IL-10 and TGF-β1 to affect osteoclast differentiation and bone resorption. In cocultures system of Tregs and mouse bone marrow macrophages (BMMs), Tregs inhibited the differentiation of osteoclasts and reduced the resorbed areas significantly and the production of both IL-10 and TGF-β1 was upregulated. When the coculture systems were pretreated with triptolide, they produced higher levels of IL-10 and TGF-β1. Our data indicate that triptolide enhances the suppressive effects of Tregs on osteoclast differentiation and bone resorption by enhancing the secretion of IL-10 and TGF-β1. Tregs are most likely involved in the triptolide-mediated regulation of bone metabolism and may provide a potential therapeutic target for the treatment of inflammatory bone destruction.

31 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
XMXiao Ma
Xiao Ma
PZPing Zhu
Ping Zhu
YDYonghe Ding
Yonghe Ding
HZHong Zhang
Hong Zhang
QQQi Qiu
Qi Qiu
Xiaolei XuXiaolei Xu
Xiaolei Xu
RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.